Feedback Link

Title here

Text here
Category: Mental Health and Crisis Services

Multidisciplinary Association For Psychedelic Studies

AKA MAPS

Santa Cruz, CA

GuideStar Quick View Everything you need to know...

Multidisciplinary Association For Psychedelic Studies

Also Known As:
MAPS
Physical Address:
Santa Cruz, CA 95060 
EIN:
59-2751953
Web URL:
www.maps.org
Leadership:
Dr. Rick Doblin, Chief Executive

Legitimacy Information

  • This organization is registered with the IRS.
  • This organization is required to file an IRS Form 990 or 990-EZ.

Institutional funders should note that an organization’s inclusion on GuideStar.org does not satisfy IRS Rev. Proc. 2011-33 for identifying supporting organizations.

Learn more about GuideStar Charity Check, the only pre-grant due diligence tool that is 100% compliant with IRS Rev. Proc 2011-33.






GuideStar Exchange Member

This organization has earned the GuideStar Exchange Seal, demonstrating its commitment to transparency.

Is this your organization's report?
Update your organization's information today!


Basic Organization Information

Multidisciplinary Association For Psychedelic Studies

Also Known As:
MAPS
Physical Address:
Santa Cruz, CA 95060 
EIN:
59-2751953
Web URL:
www.maps.org 
NTEE Category:
H Medical Research 
H99 Other Medical Research N.E.C. 
F Mental Health, Crisis Intervention 
F30 Mental Health Treatment 
W Public, Society Benefit 
W20 Government and Public Administration 
Year Founded:
1986 
Ruling Year:
1986 
How This Organization Is Funded:
Ashawna Hailey - $200,000
John Gilmore - $200,000
Anonymous - $100,000

Login or register to see this organization's full address, contact information, and more!


Mission Statement

MAPS' mission is (1) to treat conditions for which conventional medicines provide limited relief—such as posttraumatic stress disorder (PTSD), pain, drug dependence, anxiety and depression associated with end-of-life issues—by developing psychedelics and marijuana into prescription medicines; (2) to treat many thousands of people by building a network of clinics where treatments can be provided; and (3) to educate the public honestly about the risks and benefits of psychedelics and marijuana.


Expert Reviews

There are no Expert Reviews for this organization. Learn more about TakeAction@GuideStar.

Impact Statement

MAPS primary project is to investigate MDMA-assisted psychotherapy as a novel treatment for PTSD in clinical trials conducted under U.S. FDA regulations. Our goal is to ease the suffering of many thousands of people worldwide who have experienced psychological trauma.
 

Personal Reviews

Write a Review



Revenue and Expenses

Login or register to view this information.


Balance Sheet

Subscribe to GuideStar Premium to view this information, if available.


Organizational Statistics

Login or register to view this information.

 

Chief Executive

Dr. Rick Doblin

Term:

Since Jan 1986

Chief Executive Profile:

MAPS Founder and Executive Director Rick Doblin received a Ph.D. in Public Policy in 2001 from Harvard's Kennedy School of Government, where he also obtained a Master's in Public Policy in 1990. His dissertation was on the regulation of the medical use of psychedelics and marijuana, and is posted on the MAPS website. Rick has studied with Dr. Stan Grof and was in the first group to become certified as Grof Holotropic Breathwork practitioners. He has published several papers, including a follow-up study to Walter Pahnke's Good Friday experiment and Timothy Leary's Concord Prison experiment. He is married to Lynne Jones Doblin, and they have 3 children, Eden, Lilah, and Eliora.

CEO/Executive Director Statement:

Since I founded MAPS in 1986, it has been a satisfaction to encourage the renaissance in psychedelic research. Our research agenda has grown to include Phase 2 pilot studies in which we must generate preliminary data to support our claims of medical benefit. The outcome of all this work (whether or not we’re able to achieve legal prescription use) will be largely determined by our actions these next several years. We are laying the foundations for larger Phase 3 research studies that are required to prove safety and efficacy, ideally with such transparency of methodology and outcomes that the next steps will be clear to everyone.

A major milestone came in April 2010, when MAPS hosted "Psychedelic Science in the 21st Century," the largest conference in the United States to focus on clinical research with psychedelics. The conference was the first of its kind to offer continuing medical education to medical doctors, medical professionals, psychologists, and other healthcare workers. Since there is now as much clinical psychedelic research taking place worldwide as there was when psychedelic research was prohibited in 1972, we were able to have three full days of programming to educate the medical audience about the latest in clinical research. The conference spurred positive reports in major media worldwide, including the New York Times, CNN, USA Today, and Scientific American. 

In June of 2009, MAPS had another milestone. In an example of MAPS' increasing reach and professionalism we gathered therapists from seven different countries (USA, Canada, Germany, Switzerland, Spain, Israel, and Jordan) for a successful debut of MAPS’ first MDMA-assisted psychotherapy for the treatment of posttraumatic stress disorder (PTSD) therapist training program. The purpose of the training program was to prepare therapists to conduct MAPS-sponsored Phase 2 and Phase 3 psychotherapy studies in accordance with MAPS’ MDMA/PTSD treatment manual.


Board Chair

Login or register to view this information.


Board of Directors

Login or register to view this information.


Officers for Fiscal Year

Subscribe to GuideStar Premium to view this information, if available.


Highest Paid Employees & Their Compensation

Subscribe to GuideStar Premium to view this information, if available.


Program: Research

Budget:
$500,000
Category:
Medical Research
Population Served:
General Public/Unspecified

Program Description:

Since 2000, MAPS has disbursed over four million dollars to worthy research and educational projects. MAPS' major project is our 21-year effort to conduct MDMA-assisted psychotherapy research, which has just reached fruition. Now that the US, Swiss and Israel MDMA/PTSD protocols are fully approved, MAPS is finally starting our $5 million, 5 year plan to conduct the research necessary to submit data to FDA requesting prescription approval for MDMA-assisted psychotherapy for PTSD. MAPS has already raised over $800,000 for the MDMA/PTSD study. We are now seeking to raise $100,000 to complete our US MDMA/PTSD study,$65,000 for our Israeli MDMA/PTSD study,$50,000 for our Swiss MDMA/PTSD study, and $100,000 for our Swiss LSD/end-of-life anxiety study. MAPS is also seeking to develop marijuana into an FDA-approved medicine but first we need to obtain an independent source of supply (which we are trying to do at UMass Amherst). NIDA's monopoly on supply obstructs research and on 2-12-7 we have won a DEA Administrative Law Judge (ALJ) lawsuit against DEA to give a license to the UMass Amherst facility. However, DEA still must issue a final ruling in response to the ALJ recommendation. The other necessary step prior to the initiation of a $5 million, 5 year plan for marijuana is FDA-approval for the use of a vaporizer in clinical research. This step has been accomplished, even though for the last 4 years NIDA has refused to sell us 10 grams (!) of marijuana for further vaporizer research. MAPS also focuses on public education through our website and Bulletin and media contacts. In addition to reporting on the latest research in both the US and abroad, the tri-annual MAPS Bulletin includes feature articles, personal accounts, reports on conferences and allied organizations, and book reviews. Back issues are available on-line at: www.maps.org

Program Long-Term Success:

Completed treating 16 out of 20 subjects in MAPS' FDA-approved study of the use of MDMA-assisted psychotherapy in people with chronic, treatment-resistant post-traumatic stress disorder(PTSD). This is the first legal, FDA-approved study of any therapeutic use of MDMA since MDMA was criminalized in 1985.

Program Short-Term Success:

Program Success Monitored by:

Program Success Examples:


Funding Needs

As of February 2011, MAPS' top priority research project is a study of MDMA-assisted psychotherapy in US veterans with chronic posttraumatic stress disorder (PTSD), mostly from Iraq and Afghanistan and a few from Vietnam. The study will cost about $500,000 and we have raised $400,000 so far. The first subjects were treated in January 2011.


Volunteer Needs

MAPS is currently recruiting volunteers interested in helping with a variety of projects, including clerical support, clinical research support, writing and proofreading, development and fundraising, tabling at events, archival, and IT support.


Request for In-Kind Contributions


News